AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) Announces Earnings Results

Key Points

• Amneal Pharmaceuticals reported earnings of $0.23 per share for the quarter, exceeding the consensus estimate of $0.17 by $0.06.
• The stock has shown a significant market capitalization of $2.63 billion and a 52-week trading range from $6.59 to $9.48.
• Analysts maintain a generally positive outlook, with an average target price of $11.60 and several firms issuing buy ratings.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.06, Zacks reports. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. AMNEAL PHARMACEUTICALS updated its FY 2025 guidance to 0.700-0.750 EPS.

AMNEAL PHARMACEUTICALS Trading Down 1.0%

Shares of AMNEAL PHARMACEUTICALS stock opened at $8.05 on Thursday. AMNEAL PHARMACEUTICALS has a 12-month low of $6.68 and a 12-month high of $9.48. The company's 50-day moving average price is $7.97 and its 200-day moving average price is $7.96. The company has a market cap of $2.52 billion, a price-to-earnings ratio of 805.81 and a beta of 1.11.

Institutional Trading of AMNEAL PHARMACEUTICALS

Several institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of AMNEAL PHARMACEUTICALS by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company's stock valued at $793,000 after purchasing an additional 4,178 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in AMNEAL PHARMACEUTICALS by 5.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company's stock valued at $2,807,000 after acquiring an additional 16,536 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in AMNEAL PHARMACEUTICALS in the 1st quarter worth approximately $244,000. Finally, Millennium Management LLC lifted its position in AMNEAL PHARMACEUTICALS by 32.6% in the first quarter. Millennium Management LLC now owns 2,087,398 shares of the company's stock valued at $17,492,000 after purchasing an additional 512,842 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. The Goldman Sachs Group assumed coverage on AMNEAL PHARMACEUTICALS in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 price target for the company. Wall Street Zen cut shares of AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, AMNEAL PHARMACEUTICALS has an average rating of "Buy" and a consensus price target of $11.60.

AMNEAL PHARMACEUTICALS Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.